Probiotics and Nutraceuticals in Human Diseases
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 1915
Special Issue Editor
Interests: autophagy and protein metabolism in cancer and in neurodegeneration; epigenetics in cancer; nutraceuticals and probiotics in cancer and infectious diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Human districts exposed to the exterior such as the skin, the digestive tract (from mouth to the intestine), and the vagina are colonized by bacteria, viruses, and fungi that as a whole are referred to as the microbiota. With their metabolism, these microbes produce beneficial nutrients and signaling molecules, yet in circumstances causing dysbiosis, they can promote diseases. Dysbiosis, the alteration in the equilibrium within the microbiota community and the microbiota metabolism, arises from changes in the environment brought forth by infections or unhealthy dietary habits, or abuse of antibiotics. Probiotics and nutraceuticals may help to restore the correct microenvironment and thus help to prevent and to cure diseases.
In this Special Issue, we wish to collect original research and review articles highlighting the role and function of probiotics and nutraceuticals (natural products with therapeutic potential) in preventing and curing human chronic diseases such as autoimmune and inflammatory diseases, cancer, infections, and others. Particular emphasis will be on the biochemical/epigenetic/cellular mechanisms of action of probiotics and nutraceuticals and their interaction for explaining the beneficial effects.
Prof. Dr. Ciro Isidoro
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- microbiota
- prebiotics
- probiotics
- nutraceuticals
- natural products
- autoimmune diseases
- cancer
- neurodegeneration
- inflammation
- infectious diseases
